AstraZeneca PLC (AZN)vsRobinhood Markets Inc (HOOD)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
HOOD
Robinhood Markets Inc
$77.03
+0.98%
FINANCIAL SERVICES · Cap: $68.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1210% more annual revenue ($60.44B vs $4.61B). HOOD leads profitability with a 41.1% profit margin vs 17.2%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
HOOD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Intrinsic value data unavailable for HOOD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 38.5%
Large-cap with strong market position
Every $100 of equity generates 22 in profit
15.1% revenue growth
Generating 1.2B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Premium valuation, high expectations priced in
2.7% earnings growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : HOOD
The strongest argument for HOOD centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 41.1% and operating margin at 38.5%. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : HOOD
The primary concerns for HOOD are P/E Ratio, EPS Growth, Debt/Equity. Debt-to-equity of 1.68 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while HOOD is a growth play — different risk/reward profiles.
HOOD carries more volatility with a beta of 2.29 — expect wider price swings.
HOOD is growing revenue faster at 15.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 56/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Robinhood Markets Inc
FINANCIAL SERVICES · CAPITAL MARKETS · USA
Robinhood Markets Inc (HOOD) is a pioneering fintech company that has transformed the retail investing landscape since its inception in 2013 by providing a commission-free trading platform accessible via an intuitive mobile app. The firm caters to a diverse user base, allowing access to a wide array of investment vehicles, including stocks, ETFs, options, and cryptocurrencies, while prioritizing financial literacy and inclusivity. By offering innovative features such as fractional shares and cash management solutions, Robinhood positions itself as a key player in the digital brokerage sector, appealing to a new generation of investors seeking efficient and transparent ways to engage with financial markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?